Author:
Damito Stacey,Liu-An Zhongying,Faraz Haroon
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Left atrial appendage: physiology, pathology, and role as a therapeutic target;Regazzoli D;Biomed Res Int,2015
2. FDA. LAAO adverse procedural outcomes potentially more common in women. (2021). Accessed: June 8, 2023: https://www.fda.gov/medical-devices/letters-health-care-providers/left-atrial-appendage-occlusion-laao-devices-potent....
3. The WATCHMAN device and post-implantation anticoagulation management. A review of key studies and the risk of device-related thrombosis;Magdi M;Am J Cardiovasc Dis,2021
4. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial;Reddy VY;JAMA,2014
5. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial;Holmes DR Jr;J Am Coll Cardiol,2014